Arcturus Therapeutics is actively engaged in partnering discussions. Our strategic alliances fall into several categories:
- Partnering RNA medicines, including access to LUNAR and UNA Technologies
- Co-Development Opportunities
Please contact bd@arcturusrx.com regarding any business development opportunities.
January 3, 2019
Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer
read more
January 2, 2019
Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
read more
December 3, 2018
Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11
read more
